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OBJECTIVES The aim of the study was to determine the value of a cluster of metabolic risk factors in
predicting mortality after coronary artery bypass surgery (CABG).
BACKGROUND The “deadly quartet” of metabolic risk factors (i.e., obesity, diabetes, hypertension, and
hypertriglyceridemia) has been associated with coronary heart disease in healthy population
studies. The expected influence of the cluster on survival in secondary prevention remains
untested overall as well as by gender.
METHODS Patients with lipid profiles undergoing primary isolated CABG (n 5 6,428) between 1987
and 1992 were followed a median of eight years. Cox models were used to evaluate all-cause
mortality. Metabolic risk factors were incorporated as the sum of deadly quartet risk factors
present in each patient (0 to 4). The role of gender as it relates to survival and metabolic risk
clusters was also examined.
RESULTS The sum of deadly quartet risk factors showed a significant relationship to mortality as the
hazard ratio increased from 1.64 (confidence interval [CI] 5 1.34–2.01) for one risk factor
to 3.95 (2.73–5.69) for four risk factors. Annualized mortality ranged from 1% per year in
patients with no risk factors to 3.3% per year in patients with all four risk factors. Within
gender, the hazard ratio associated with four risk factors was 2.58 for men and 13.39 for
women. The expected clustering of risk factors was 8% compared to the observed clustering
of 10% in men and 21% in women.
CONCLUSIONS This cohort showed risk factor clustering beyond that expected due to chance, particularly in
women. Even after revascularization, survival is diminished for patients with members of a
family of metabolic risk factors at the time of surgery. (J Am Coll Cardiol 2000;36:1159–65)
© 2000 by the American College of Cardiology
The “deadly quartet” (obesity, diabetes mellitus, hyperten-
sion, and hypertriglyceridemia) was characterized by Kaplan
(1) with inspiration from Reaven (2), who defined the
metabolic syndrome. This grouping of known metabolic
risk factors is highly associated with coronary heart disease
(CHD) (3,4), and typically viewed as associated with insulin
resistance (5). The increase in risk for cardiovascular disease
(CVD) as the number of risk factors progressively increases
has been well documented (6). However, the demonstration
of clustered risk in the primary prevention setting cannot
necessarily be extrapolated to secondary prevention efforts.
Although a recent analysis characterized risk clustering and
16-year outcomes in the follow-up of the healthy population
of the Framingham cohort (7), both the degree of clustering
and its impact on mortality have not been characterized in
those with established coronary artery disease (3).
Separating the contributions of each of these factors to
atherogenic risk has been complex. There is evidence that
the members of the deadly quartet interact with one another
as they relate to CHD (8–12), and even potentially repre-
sent a common metabolic abnormality (5). Defining the
ultimate influence on mortality of some or all members of
this metabolic quartet in patients with CHD could reshape
current treatment strategies in secondary prevention (13–
15). Such risk stratification could also be factored into
decisions related to the benefits associated with surgical
revascularization procedures (i.e., coronary artery bypass
surgery). For example, the presence of diabetes, one member
of the quartet, has already been reported to lead to greater
mortality and event rates after coronary artery bypass graft
surgery (CABG) (16–18).
We examined the post-CABG registry at the Cleveland
Clinic to determine whether the deadly quartet resulted in
increased mortality over the average eight years of follow-
up. Further, we explored the role of gender in the suscep-
tibility to these clustered risk factors.
METHODS
Study population. Nine thousand five hundred and forty-
four (9,544) patients had primary isolated CABG at the
Cleveland Clinic between 1987 and 1992. Exclusions were
made for hospital death (n 5 210) and lack of complete
lipid evaluations (total cholesterol, HDL-c [high density
lipoprotein cholesterol] and triglycerides) performed prior
to surgery (n 5 2,906). The resultant study cohort num-
bered 6,428 patients. Low density lipoprotein cholesterol
[LDL-c] was not considered, because of inability to accu-
rately measure LDL-c when triglycerides exceed 400 mg/dl.
Lipid measurements were drawn in the fasting state a
median of five days before surgery (65% before surgical
admission). The Cleveland Clinic Foundation laboratory
was standardized by the Centers for Disease Control [Part
III], with accreditation through the College of American
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Pathology during the study period. Specifically trained
personnel abstracted data from the medical record using a
standardized data-collection form that required either nu-
meric entries or checks (yes/no) for the risk factors of
interest. The outcome for this study was all-cause mortality
as obtained from either routine patient/family contact or the
Social Security Administration mortality index. Median
follow-up time for the 5,568 surviving patients was 8.2
years.
Statistical analyses. The deadly quartet risk factors are
defined as history of diabetes mellitus (DM) based on
known pharmacologic treatment of diabetes, hypertension
established through repeated systolic blood pressure
.140 mm Hg and/or diastolic blood pressure .90 mm Hg
or pharmacologic treatment of hypertension, body mass
index (BMI) in the top quartile (.30.0) and triglyceride
(TG) in the top quartile (.219 mg/dl). The upper quartiles
were established within the study cohort because of con-
cerns about extrapolating parameters from the primary
prevention setting to secondary prevention. The upper TG
quartile from this study corresponds approximately to the
upper decile of similar-age subjects in the Framingham
Study (19), and the Lipid Research Clinic Prevalence study
(20). The sum of these risk factors is represented by integer
values from zero to four.
The probability of having a given risk factor is character-
ized by the binomial distribution, and the incidence of
having a given risk factor ranges from 0.20 for diabetes to
0.55 for hypertension in this population. The expected
probability of having 0, 1, 2, 3 or 4 risk factors has been
estimated based on a binomial expansion assuming inde-
pendent risks. Expected distributions were based on com-
bined data for men and women because we had no a priori
expectations of gender differences (7). Cox proportional
hazards modeling (PROC PHREG, SAS Institute, Cary,
North Carolina) was used to assess the relative importance
of baseline risk factors to the end points (21). Tied event
data were handled using Efron’s method of approximation
(22). Overall model significance was assessed with
likelihood-ratio tests, and significance of each variable in the
model with the Wald test. Dummy variable coding was
developed within the framework of Cox proportional haz-
ards modeling to compare patients with 1, 2, 3 and four of
the deadly quartet components to patients with none of the
components. Hazard ratios (HRs) are presented (with 95%
confidence intervals [CIs]) to show the risk of an event
when the factor is present. These risk estimates represent
the average risk when 1, 2, 3, or 4 risk factors are present
and do not speak to risk associated with a specific risk factor.
A three-step strategy was taken to evaluate the impor-
tance of the deadly quartet. First, unadjusted HRs were
calculated followed by age-adjusted HRs. Finally, a model
adjusting for age and surgical variables (left ventricular
function, extent of disease, and internal thoracic artery
[ITA] use) was developed. To determine whether the
conclusions regarding risk progression hinged on a single
member of the deadly quartet, four models were built
sequentially, holding each individual risk factor to zero (not
presented).
Information was not available regarding certain medica-
tions (e.g., hormone replacement therapy [HRT], lipid-
lowering agents) that are known to impact TG values.
Therefore, analyses were undertaken to determine the like-
lihood that conclusions relating the deadly quartet sum to
mortality could be jeopardized by TG category misclassifi-
cation. Progressive percentages of “presumed” misclassified
patients were randomly identified and reallocated to the
opposite TG group (e.g., high TG due to HRT reclassified
as normal TG). Hazard ratios for the deadly quartet sum
were recalculated to determine consistency with the re-
ported relationship. Both a gender main effect and an
interaction term between gender and the sum of deadly
quartet risks were included in the fully adjusted model to
examine the potential role of gender with regard to all-cause
mortality. A statistically significant interaction term would
lead to examination of models stratified by gender. Model-
ing included testing the assumption of proportional hazards.
RESULTS
Patient characteristics. Table 1 shows the presentation
characteristics of this post-CABG population with regard to
the relevant risk factors. The p values resulting from gender
comparisons indicate that women typically show greater
risk. Of patients undergoing primary isolated CABG during
this time frame, 2,906 (31%) were missing either TG or
HDL-c values before surgery. Cases missing lipids were
more likely to be emergent and use saphenous vein grafts
than were those with complete lipid profiles. The group
with missing values also had more women, was older and
had worse left ventricular function than did those with
complete lipid profiles (p 5 0.001 for all). Consequently, a
worse survival outlook was seen in those patients without
baseline lipid measurements.
All-cause mortality for the study population was 13%
(n 5 860). Women suffered a greater raw mortality rate
than did men (17% vs. 12%), but this was not statistically
significant after adjusting for age, surgical variables and the
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identified metabolic risk factors (HR 5 0.95, CI 5 0.81 to
1.12, p 5 0.55). The mortality rate increased as the number
of deadly quartet risk factors increased in all cases (Fig. 1,
p , 0.001 for all).
Expected risk factor distributions and observed distribu-
tions are shown in Figure 2. An enhanced frequency of
observed versus expected distributions was noted for those
with zero risk factors and those with three or four risk
factors.
Deadly quartet effect. We first examined the univariate
risk associated with the sum of the four deadly quartet
components (e.g., a patient with DM and TG 5 230 mg/dl
would have two of the four). After the univariate look,
age-adjusted models were built followed by age- and surgi-
cal variable-adjusted models. Adjustments for smoking
status and race did not affect the results materially (data not
shown). Table 2 shows that the hazard associated with the
deadly quartet increased from 1.64 to 3.95 as the risk factors
accumulated whether adjusted or not. The proportional
hazards assumption was not perfectly met. Therefore, the
estimated HRs for the number of deadly quartet risk factors
are conservative as they represent an average hazard over the
course of the study.
Based on the analyses involving TG misclassification, at
least 60% of patients would have to have misclassified TGs
to significantly impact the observed relationship between
the deadly quartet sum and mortality. A piecewise expo-
nential model accounting for variable hazards across time
corroborated the results of the Cox models (data not
Figure 1. Raw incidence of mortality overall and by gender. Open bars 5
overall risk factors; hatched bars 5 male risk factors; solid bars 5 female
risk factors.
Figure 2. Expected (line) and observed (bars) prevalence of patients with
zero, one, two, three or four of the deadly quartet risk factors (hyperten-
sion, diabetes, hypertriglyceridemia, obesity). Open bars 5 overall risk
factors; hatched bars 5 male risk factors; solid bars 5 female risk factors.




Number 6,428 5,175 1,253
Age 62 6 10 61 6 10 65 6 9 , 0.001
Hx of DM 1313 (20%) 917 (18%) 396 (32%) , 0.001
Hx of HTN 3549 (55%) 2689 (52%) 860 (69%) , 0.001
TG . 219 mg/dl 1607 (25%) 1230 (24%) 377 (30%) , 0.001
BMI . 30 1679 (26%) 1261 (24%) 418 (33%) , 0.001
Race , 0.001
White 5833 (91%) 4660 (90%) 1173 (94%) —
Black 109 (2%) 73 (1%) 36 (3%) —
Other 486 (8%) 442 (9%) 44 (4%) —
Smoking 3230 (50%) 2723 (53%) 507 (41%) , 0.001
2- 3-Vessel DX† 6050 (94%) 5175 (95%) 1156 (92%) 0.002
Severe LVF‡ 570 (9%) 466 (9%) 104 (8%) 0.43
ITA used 5528 (86%) 4606 (89%) 922 (74%) , 0.001
Deadly quartet sum
0 1599 (25%) 1425 (28%) 174 (14%) , 0.001
1 2442 (38%) 2011 (39%) 431 (34%) 0.003
2 1597 (25%) 1218 (24%) 379 (30%) , 0.001
3 648 (10%) 434 (8%) 214 (17%) , 0.001
4 142 (2%) 87 (2%) 55 (4%) , 0.001
*p Values resultant from male versus female comparison. †Two- or three-vessel coronary artery disese (stenosis .50%). ‡Severe left ventricular dysfunction (ejection fraction
,20%).
HTN 5 hypertension.
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shown). The addition of HDL-c and total cholesterol did
not appreciably change risk estimates associated with the
deadly quartet and provided no additional predictive power
(p 5 0.86, p 5 0.35, respectively).
It was necessary to determine whether any one of the
deadly quartet components was necessary to the expression
of mortality risk. If, for example, diabetes were the one risk
factor that was necessary for the expression of mortality risk,
then one would expect mortality risk to be muted in the
absence of diabetes. Therefore, the mortality risk was
estimated sequentially when each component risk was ab-
sent. Similar HRs were seen for even a single risk factor in
the absence of diabetes (HR 5 1.58, CI 5 1.29–1.95),
obesity (HR 5 1.61, CI 5 1.31–1.98), hypertension (HR 5
1.59, CI 5 1.24–2.04) and hypertriglyceridemia (HR 5
1.73, CI 5 1.61–2.57). Furthermore, we saw little evidence
that the particular cluster of risk factors altered mortality
risk significantly when at least three factors were present.
Hazard ratios ranged from 2.20 (1.49–3.24) with obesity,
hypertension and hypertriglyceridemia, to 3.49 (1.96–6.20)
with diabetes, obesity and hypertriglyceridemia.
The effects of the remaining deadly quartet risk factors in
relationship to obesity were reviewed in detail because of the
emphasis placed on obesity in Kaplan’s original efforts. The
effects of one, two or three risks by obesity status as defined
by BMI in the top quartile (.30.0) were estimated. For
nonobese patients, the HR for one risk was 1.61 (CI 5
1.31–1.98), for two risks 2.07 (CI 5 1.64–2.62) and for
three risks 2.74 (CI 5 1.90–3.96). For obese patients, the
impact of additional risk factors was seen for three risks
(HR 5 2.21, CI 5 1.41–3.47), but not one (HR 5 0.99,
CI 5 0.68–1.52) or two (HR 5 1.36, CI 5 0.86–1.99)
additional risks. Nonobese patients were more likely to have
no deadly quartet risk factors than obese patients (34% vs.
19%). In contrast, obese patients were more likely to have at
least two other deadly quartet risk factors than nonobese
patients (38% vs. 21%).
Gender effect. Progressing with the model adjusting for
age and surgical variables, gender issues were examined. No
evidence was seen of a gender effect on survival after
adjustment for age, surgical variables, and the deadly quartet
(HR 5 0.95, 95% CI 5 0.81–1.12, p 5 0.55). However, the
differing presentation characteristics of men and women
leave the question of whether men and women experience
differential effects from the presence of the deadly quartet
risk factors. An interaction term between gender and the
sum of the quartet components was statistically significant
(p 5 0.01).
The positive interaction finding provides motivation to
examine the effects of the deadly quartet by gender. The
progressive increase in presence of deadly quartet compo-
nents is clear for both men and women. The risk for men
progressed from 1.49 (1.20–1.84) to 1.80 (1.43–2.29) to
2.31 (1.74–3.07) to 2.58 (1.53–4.36) as the number of
Figure 3. Kaplan-Meier survival curves showing the estimated risk of all-cause mortality for men with 0, 1, 2, 3 and 4 of the deadly quartet risk factors
(obesity, diabetes, hypertension and hypertriglyceridemia).
Table 2. Deadly Quartet Hazard Ratio (HR) Estimating the Risk of Mortality with 95% Confidence Intervals (95% CI) Estimated
from Cox Proportional Hazards Models Unadjusted, Age-Adjusted and Age- and Surgical Variable-Adjusted*
Quartet
Unadjusted Age Adjusted Age 1 Surgical Adjusted
HR 95% CI HR 95% CI HR 95% CI
0 of 4 1.00 — 1.00 — 1.00 —
1 of 4 1.73 1.42–2.12 1.62 1.32–1.99 1.64 1.34–2.01
2 of 4 1.94 1.57–2.40 1.94 1.57–2.40 1.95 1.57–2.41
3 of 4 2.52 1.97–3.23 2.61 2.04–3.34 2.52 1.97–3.23
4 of 4 3.64 2.53–5.25 4.13 2.87–5.96 3.95 2.73–5.69
*Operative year, left ventricular function, extent of disease, and ITA use.
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deadly quartet risks increased from 1 to 4 (Fig. 3). The effect
was even more dramatic in women as HRs moved from 4.43
(2.04–9.62) to 5.03 (2.31–10.94) to 6.32 (2.85–14.04) to
13.39 (5.66–31.68) as the deadly quartet risk factor sum
increased from 1 to 4 (Fig. 4). An examination of the CIs
shows that the high end of the 95% CI in men is almost
always less than the low end of the 95% CI in women.
DISCUSSION
We have found in subjects with relatively severe coronary
atherosclerotic disease and subsequent CABG a striking
clustering of metabolic risk factors, previously reported as
part of the “deadly quartet”. Over 90% of the 860 patients
who died during follow-up had at least one element of the
deadly quartet. The concurrent presence of three or more
members of the quartet occurs in 10% of men and 21% of
women in the pre-CABG population at our institution, and
among these groups one in five men and one in four women
died over the course of follow up. In contrast, in patients
without any of the deadly quartet risk factors, 1 in 10 men
died and 1 in 20 women died during the follow-up period.
“Common soil.” Analysis of a cluster of risk factors, all
metabolically interrelated, has not been previously per-
formed in a group of CHD subjects. Although the physi-
ologic lines may be somewhat unclear, this cluster of factors
may represent primarily the presence of one disorder, which
has multiple clinical presentations (5,8,23). The frequency
of those without any of the risk factors is substantially more
than expected, and the frequency of those with multiple
metabolic risk factors (3 or 4) is increased beyond that
expected. Therefore, lack of any members of the cluster is
interpreted as lack of the substrate for the disorder, absence
of the “common soil” (5) for diabetes and atherogenesis, and
clear protection from even expressing one member of the
cluster. It does not appear that any single risk factor is
pivotal to the expression of mortality risk. In contrast, with
three risk factors, the “soil” for the disorder is fertile, and
expression is enhanced.
Gender. We have observed a twofold greater prevalence of
this composite in women than in men, suggesting that this
metabolic quartet is a more typical basis for vascular disease
in women. The individual cardiovascular implications of
TG and DM are known to be more relevant in women
(19,24). Now, presented herein, when all four risk factors
are present in a woman, the risk for death is over 10-fold,
compared to a risk of death in a man of two- to threefold.
The relatively small number of patients with all four risk
factors present leads to fairly wide CIs; however, it appears
that women have more risk for death than do men when one
or more members of the quartet are expressed, and they have
a tendency for reduced mortality when none are present.
Indeed, when adjustment is made for this metabolic clus-
tering, no difference in mortality was noted between men
and women post-CABG, consistent with results of the
Bypass Angioplasty Revascularization Investigation (BARI)
(25).
Influence of body mass. Increments in BMI are associated
with increasing rates of CHD and mortality (26), and they
form a major element of the Kaplan quartet (1). Though
some have suggested that body mass is independently
correlated with vascular disease, this is difficult to prove
owing to the strong interactions with other traditional risk
factors (27–29). After dividing patients according to their
baseline BMI (, or . 30.0), the composite of the three
remaining risk factors markedly decreases in prevalence in
those below the top quartile, while the probability of death
remains the same (i.e., if you have hypertension, hypertri-
glyceridemia and diabetes, the risk of death appears similar
whether your BMI is high or low). The higher incidence of
metabolic clustering with greater BMI suggests that the
dramatic trend for increasing obesity in the U.S. is an
ominous sign (30).
Figure 4. Kaplan-Meier survival curves showing the estimated risk of all-cause mortality for women with 0, 1, 2, 3 and 4 of the deadly quartet risk factors
(obesity, diabetes, hypertension and hypertriglyceridemia).
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Summary. Based on recorded information (indeed, the
presence of some quartet members may escape recognition
or documentation), we have found that a clustering of
metabolic features is evident in CAD patients, expressed
beyond that anticipated by chance alone. As in subjects
without known CAD, those with significant disease—even
after the protection of surgical revascularization—suffer a
substantial increase in mortality when this syndrome is
expressed. Important tools to protect against this risk
cluster, e.g., fibric acid derivatives to improve intermediate
lipoprotein processing and to decrease TG levels (31),
angiotensin-converting enzyme inhibitors to reduce plas-
minogen activator inhibitor-1 levels (increased in this syn-
drome) (32–34), decrease sympathetic activity and enhance
insulin receptor sensitivity (35), and/or metformin (36) and
troglitazone to upregulate insulin sensitivity, are becoming
understood and available. Statin therapy in diabetic patients
is at least as therapeutic as in nondiabetics (37–39), includ-
ing post-CABG patients (40), and it should be considered
in those with this metabolic cluster. In subjects preparing to
have CABG, and perhaps in all those with CAD, expres-
sion of members of the deadly quartet can be a prequel to
fatal outcomes and should motivate global treatment strat-
egies beyond the simple attention dedicated to the present-
ing feature of the deadly cluster, especially in women.
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